Trials / Completed
CompletedNCT06340607
Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
Impact of Neohepatic Albumin-Bilirubin Scores on Renal Outcomes Following Living-donor Liver Transplantation: Propensity Score Analysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,422 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.
Detailed description
Acute kidney injury (AKI) after liver transplantation (LT) significantly affects patient and graft outcomes. The Albumin-Bilirubin (ALBI) score, an objective and sensitive index of liver function, has potential applicability in predicting outcomes following LT. This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.
Conditions
Timeline
- Start date
- 2012-01-05
- Primary completion
- 2020-01-05
- Completion
- 2022-12-31
- First posted
- 2024-04-01
- Last updated
- 2024-04-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06340607. Inclusion in this directory is not an endorsement.